Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32224306

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 May
First author
Trigo J

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 May;21(5):605-607. doi: 10.1016/S1470-2045(20)30097-8.
    note
    Source null
    related pmid
    32224305
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Dec;21(12):e553. doi: 10.1016/S1470-2045(20)30676-8.
    note
    Source null
    related pmid
    33271113
    relationship
    Erratum in

Authors and identifiers

  1. name
    Trigo J
    type
    Author
  2. name
    Subbiah V
    type
    Author
  3. name
    Besse B
    type
    Author
  4. name
    Moreno V
    type
    Author
  5. name
    López R
    type
    Author
  6. name
    Sala MA
    type
    Author
  7. name
    Peters S
    type
    Author
  8. name
    Ponce S
    type
    Author
  9. name
    Fernández C
    type
    Author
  10. name
    Alfaro V
    type
    Author
  11. name
    Gómez J
    type
    Author
  12. name
    Kahatt C
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Trigo J
    type
    Author
  2. name
    Subbiah V
    type
    Author
  3. name
    Besse B
    type
    Author
  4. name
    Moreno V
    type
    Author
  5. name
    López R
    type
    Author
  6. name
    Sala MA
    type
    Author
  7. name
    Peters S
    type
    Author
  8. name
    Ponce S
    type
    Author
  9. name
    Fernández C
    type
    Author
  10. name
    Alfaro V
    type
    Author
  11. name
    Gómez J
    type
    Author
  12. name
    Kahatt C
    type
    Author
bibliography ids
  1. nci-bib-58b09c9231c19edd68a251b7
book metadata
content sha256
77f50f7a0734c41b7dcdb7113814db7ca2205278673d2a27100f3ee498b6729e
document type
citation
dois
  1. 10.1016/S1470-2045(20)30068-1
electronic publication date
display
2020 Mar 27
precision
day
year
2020
evidence scope
bibliographic_metadata_only
id
pubmed:32224306
immutable id
pubmed:32224306@77f50f7a0734c41b7dcdb7113814db7ca2205278673d2a27100f3ee498b6729e
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
5
name
The Lancet. Oncology
nlm unique id
100957246
pages
645-654
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 May;21(5):605-607. doi: 10.1016/S1470-2045(20)30097-8.
    note
    Source null
    related pmid
    32224305
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Dec;21(12):e553. doi: 10.1016/S1470-2045(20)30676-8.
    note
    Source null
    related pmid
    33271113
    relationship
    Erratum in
outcomes validated
false
pmid
32224306
provenance
batch id
40d9eae1f1d369f13109
provider
NCBI PubMed ESummary
record sha256
18e146e1a02c4250cd56b9556f75da0f97399daa4ab1dfc63f61ed7444e4a9b7
response sha256
03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
retrieved at
2026-09-09T23:47:52.637547+00:00
publication date
display
2020 May
precision
month
year
2020
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32224306/
title
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

Preserved source evidence · Not medical advice